EVCARCO (OTC.BB:EVCA) is pioneering a new way to meet the demands of 21st century car buyers. EVCARCO is bringing to market eco-friendly vehicles with an emphasis on performance and affordability and the latest in developed technology. The board of EVCARCO is pleased to announce that, pursuant to a strong demand from the US Federal Government to meet environmental standards in relation to its Federal Military fleet, EVCARCO will be working with VENTA Inc. and several third party organizations to create Military grade AEV and Hybrid Diesel Electric units.
The move is part of an EVCARCO recent corporate shift aimed at increasing revenue through contracting and sourcing of units suitable for Government RFPs.
EVCARCO has been working on projects with the US Federal Government as announced in previous releases since first quarter of 2010; the trials have given the management of EVCARCO insight into the needs and requirements of the Federal Government and, with this knowledge, the corporation stands at a significant advantage in respect to sourcing specific AEV and Hybrid Units for the Military.
The US Military through TARDEC has set a strong precedent relating to adoption of Alternative energy units into the US Military. TARDEC is the U.S. Army’s lead organization for ground vehicle systems integration, engineering and technology development.
Initial development of units will be entered into testing phase by late 2010 with “Real World” Government testing anticipated for early 2011.
AFVs are vehicles that operate on alternative fuels, such as methanol, ethanol, compressed natural gas, liquefied petroleum gas, or electricity, as designated by the U.S. Department of Energy. Some AFVs that can run on conventional fuels like gasoline, as well as alternative fuels, are called dual-fueled vehicles.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reports top-line efficacy and safety results from a Phase II clinical trial utilizing Corticotropin Releasing Factor (CRF1) receptor antagonist GSK561679 in patients currently experiencing a major depressive episode. This double-blind, placebo controlled trial randomized 150 patients into two treatment arms, 350 mg of GSK561679 daily and placebo, and was conducted in the United States by GlaxoSmithKline (GSK) under the GSK/Neurocrine CRF1 collaboration. The primary endpoint was change from baseline in the Bech Melancholia scale at Week 6 and a key secondary endpoint was change from baseline in the HAMD-17 scale at Week 6.
Results of statistical analysis using the intent-to-treat population revealed no benefit of GSK561679 compared with placeboon both the Bech Melancholia and HAMD-17 endpoints. The top-line results are based on the six week placebo-controlled portion of the study for the intent to treat population of 145 patients. From a safety perspective, there were no significant adverse events, and the drug was generally well tolerated.
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Neurocrine Biosciences, Inc product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine related diseases and disorders.
NeuroMetrix, Inc. (Nasdaq: NURO), a health care company transforming patient care through neurotechnology, reports its financial results for the quarter ended June 30, 2010.
Total revenues for the second quarter of 2010 were $3.9 million, compared with $6.8 million for the second quarter of 2009. Revenues in the quarter were comprised of 13% medical equipment sales and 87% consumables sales in comparison with 10% and 90%, respectively, for the second quarter of 2009. Medical equipment sales consist of nerve testing devices (NC-stat and ADVANCE) and related modules, and service agreement revenues. Consumables sales include single use nerve-specific electrodes, EMG needles, and other accessories. The January 1, 2010 change in Medicare reimbursement for nerve conduction studies using pre-configured electrodes such as those used with NC-stat contributed to the decline in revenue between the two quarterly periods. This decline primarily reflected a 22% reduction in electrode average selling price and a 25% decrease in electrodes sold. Gross margin in the second quarter of 2010 was 63.5% of total revenues compared with 71.4% for the second quarter of 2009. Net loss for the second quarter of 2010 was $4.5 million, or $(0.20) per share. In comparison, net loss for the second quarter of 2009 was $1.8 million, or $(0.13) per share.
For the six months ended June 30, 2010 total revenues were $7.4 million compared with $13.6 million for the comparable period in 2009. Gross margin for the six months was 63.6% of total revenues compared with 71.5% for the six month period in 2009. Net loss for the six month period ended June 30, 2010 was $9.3 million or ($0.40) per share. In comparison, net loss for the comparable period in 2009 was $3.0 million or ($0.22) per share.
Neustar, Inc. (NYSE: NSR) reports the launch of Ultra DDI, a new offering that seamlessly integrates internal DNS, DHCP and IP Address Management (IPAM) operations. Ultra DDI allows Neustar customers to outsource their entire infrastructures while allowing them to retain full control over day-to-day changes.
The Neustar Ultra DDI managed service includes networking equipment using Infoblox appliances, as well as issue resolution, software updates, equipment replacement and hardware lifecycle replenishment. In addition, Neustar experts conduct around-the-clock monitoring and maintenance of back-end DNS and DHCP operations, watching nearly 50 health and usage parameters for proactive infrastructure management and issue response. Neustar also retains a database of critical DNS and DHCP data points to enable trending and planning for future growth and management.
“Neustar exists to simplify network complexity,” said Alex Berry, senior vice president of Neustar’s Internet Infrastructure Services (IIS) group. “DNS and DHCP are the linchpins for unifying networks and enhancing communications � and it is becoming increasingly time- and labor-intensive for our customers to juggle multi-vendor management and network troubleshooting on their own. More customers are realizing that it simply makes good business sense to trust Neustar. We have built a sterling reputation in delivering and managing the core services underlying IP network infrastructures.”
Neustar, Inc. provides market-leading and innovative solutions and directory services that enable trusted communication across networks, applications and enterprises around the world. Leveraging a unique directory platform and proprietary, patented technologies, Neustar’s UltraDNS Services � the company’s comprehensive suite of managed DNS offerings � provides a range of infrastructure solutions to organizations that rely on the Internet for their critical business processes, applications and services. Today, UltraDNS Services are used by more than 3,000 enterprises and TLD infrastructure customers worldwide, and currently power the resolution of nearly 20 million global Internet domains.
No comments:
Post a Comment